Alanna A Morris MD
Adult Congenital Heart Disease, Heart Failure & Transplantation
Physician
Are you Dr. Morris?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Alanna Morris, MD is a cardiologist in Gainesville, Georgia. She is currently licensed to practice medicine in Georgia and Massachusetts.
Education & Training
- Emory University School of MedicineFellowship, Cardiovascular Disease, 2008 - 2012
- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2005 - 2008
- Harvard Medical SchoolClass of 2005
Certifications & Licensure
- GA State Medical License 2008 - 2025
- MA State Medical License 2007 - 2009
- American Board of Internal Medicine Advanced Heart Failure and Transplant Cardiology
- American Board of Internal Medicine Cardiovascular Disease
Publications & Presentations
PubMed
- 2 citationsIdentification of indirect CD4T cell epitopes associated with transplant rejection provides a target for donor-specific tolerance induction.Zhuldyz Zhanzak, Aileen C Johnson, Petra Foster, Maria A Cardenas, Anna B Morris
Immunity. 2025-02-11 - Measuring Representativeness in Clinical Trials.Allen Sanyi, Samuel Byiringiro, Sanaz Dabiri, Mireille Jacobson, Amanda Boyd
Circulation. 2025-02-04 - Integrating Out-of-Pocket Costs Into Shared Decision-Making for Heart Failure With Reduced Ejection Fraction: A Stepped-Wedge Trial (POCKET-COST-HF).Neal W Dickert, Candace D Speight, Madeline Balser, Henry Biermann, J Kelly Davis
Circulation. Cardiovascular Quality and Outcomes. 2025-01-01
Press Mentions
- Bayer Submits Supplemental New Drug Application to U.S. FDA Seeking New Indication for KERENDIA® (Finerenone) in Patients with Heart Failure with Left Ventricular Ejection Fraction of ≥40%January 10th, 2025
- Bayer Submits Supplemental New Drug Application to U.S. FDA Seeking New Indication for KERENDIA® (Finerenone) in Patients with Heart Failure with Left Ventricular Ejection Fraction of ≥40%January 10th, 2025
- ACC/AHA Clarify How Social Determinants of Health Impact CVDAugust 28th, 2024
- Join now to see all